Showing 3171-3180 of 4063 results for "".
- Johnson & Johnson Presents New Data on ACUVUE OASYS MAX 1-Day Contact Lenseshttps://modernod.com/news/johnson-johnson-presents-new-data-on-acuvue-oasys-max-1-day-contact-lenses/2482523/Johnson & Johnson will present data at Academy of Optometry 2024 on the ACUVUE OASYS MAX 1-Day family of contact lenses including contrast sensitivity, brightness of natural images, lens handling, and more. Data will also be presented on myopia management, use of digital technologie
- Epion Presents Survey on Keratoconus Highlighting Need for Accessible Treatmentshttps://modernod.com/news/epion-presents-survey-on-keratoconus-highlighting-urgent-need-for-accessible-treatments/2482518/Jonathan H. Talamo, MD, Chair of the Board at Epion Therapeutics, presented findings at the Eyecelerator@AAO 2024 conference on the current state of keratoconus (KC) management in the United States, highlighting a critical gap in treatment for the progressive eye disease. Results f
- Campaign Highlights the Role of Caregivers in Eye Health Awareness for Retinal Conditionshttps://modernod.com/news/campaign-highlights-the-role-of-caregivers-in-eye-health-awareness-for-retinal-conditions/2482515/This fall, Prevent Blindness and Regeneron are expanding their eye health awareness initiative, 'The Gr8 Eye Movement,' to emphasize the crucial role caregivers play in the health of loved ones at risk for serious retinal conditions. Originally launched in 2022, the Gr8 Eye Movement campa
- Genentech Announces Phase 4 Results for Vabysmo in Treating DME Among Underrepresented Populationshttps://modernod.com/news/genentech-announces-phase-4-results-for-vabysmo-in-treating-dme-among-underrepresented-populations/2482514/Genentech revealed promising 1-year findings from its phase 4 ELEVATUM study for Vabysmo (faricimab-svoa) for diabetic macular edema (DME) in racial and ethnic groups typically underrepresented in clinical trials. Results presented at the American Academy of Ophthalmology (AAO) 2024 annual m
- Ocuphire Acquires Gene Therapy Company Opus Geneticshttps://modernod.com/news/ocuphire-acquires-gene-therapy-company-opus-genetics/2482508/Ocuphire Pharma announced an all-stock acquisition of Opus Genetics, a clinical-stage gene therapy company specializing in inherited retinal diseases (IRDs). As part of the deal, the combined company will be renamed Opus Genetics, effective October 23, 2024, and will begin trading under the
- Study: SLT Slows Glaucoma Progression Compared to Topical Eye Dropshttps://modernod.com/news/study-slt-slows-glaucoma-progression-compared-to-topical-eye-drops/2482506/A new study presented at the American Academy of Ophthalmology (AAO) this past weekend found that selective laser trabeculoplasty (SLT) slowed glaucoma progression by 29% compared to patients using daily eye drops.[1] “Select
- Life Biosciences Presents New Data on Novel Gene Therapy at AAOhttps://modernod.com/news/life-biosciences-presents-new-data-on-novel-gene-therapy-at-aao/2482505/Life Biosciences announced new data at the 2024 American Association of Ophthalmology (AAO) annual meeting on its gene therapy for optic neuropathies. According to Life Biosciences, the data replicates earlier findings in nonhuman primates (NHPs) and provides insights into the dosing and tim
- AAO: Home OCT Device Improves Care for AMD Patients, Reduces Costs and Burdenhttps://modernod.com/news/aao-home-oct-device-improves-care-for-amd-patients-reduces-costs-and-burden/2482499/A newly approved home-based OCT device developed by Notel Vision is allowing patients to monitor their own eye health between appointments, providing physicians with crucial data without requiring in-office visits, according to an AAO news release. A study presented today at AAO 2024 suggest
- Exponential Increase in Anti-VEGF Treatments Linked to Higher Risk of Complications in Cataract Surgery, Study Findshttps://modernod.com/news/exponential-increase-in-anti-vegf-treatments-linked-to-higher-risk-of-complications-in-cataract-surgery-study-finds/2482498/In the largest study of its kind, Canadian researchers from the University of Toronto have identified a higher risk of complications in cataract surgery patients with a history of anti-VEGF injections. These findings will be presented this week at AAO 2024, the 128th annual meeting of the America
- Ocular Therapeutix Announces Accelerated Timelines for SOL-1 Registrational Trial of Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-accelerated-timelines-for-sol-1-registrational-trial-of-axpaxli-in-wet-amd/2482490/Ocular Therapeutix announced an acceleration of the SOL-1 phase 3 registrational clinical trial of Axpaxli for wet age-related macular degeneration (wet AMD). The company now expects to complete enrollment and randomization by the end of 2024, ahead of previous guidance to finish by the first qua